Diagnosis and Management of COPD

Initial Assessment and Diagnosis

The American Thoracic Society recommends confirming COPD diagnosis with spirometry, looking for post-bronchodilator FEV1/FVC ratio <0.70, which is diagnostic according to guidelines 1
Patients with COPD should be assessed for common comorbidities, particularly cardiovascular disease and lung cancer, which are frequently associated with COPD and contribute significantly to morbidity and mortality 2, 3
The severity of airflow limitation should be evaluated, as COPD is a progressive disorder that passes through mild and moderate phases before becoming severe 4
Screening for hypoxemia is necessary, as it can lead to pulmonary hypertension and cor pulmonale in severe disease, indicating poor prognosis 4

Inhaled bronchodilator therapy should be started to relieve symptoms, even if spirometric changes are not seen in all patients 5
The American College of Chest Physicians suggests considering one of three groups of bronchodilators: β2-agonists, anticholinergic drugs, or methylxanthines 5

The American Heart Association recommends addressing both COPD and cardiovascular risk factors aggressively, as they share common pathobiological pathways 2, 3
Approximately 26% of deaths in patients with moderate to severe COPD are due to cardiovascular causes, 21% due to cancer, and only 35% directly attributable to COPD 2

The British Thoracic Society recommends evaluating the need for long-term oxygen therapy in patients with severe COPD and hypoxemia, as it is the only treatment known to improve prognosis in this population 4
Target oxygen saturation of 88-92% for patients with respiratory acidosis 5